Treatment Of Cutaneous Larva Migrans Research Articles

Reflectance Confocal Microscopy and Dermoscopy For the Diagnosis and Treatment of Cutaneous Larva Migrans

We describe a 39-year-old woman with a 1-month-old linear erythema diagnosed with cutaneous larva migrans by reflectance confocal microscopy (RCM). This case reveals that the great significance of diagnosing and treating cutaneous larva migrans (CLM) by RCM and dermoscopy, which might provide novel insights into dermatological clinical practice.

Dermoscopy Before and After Treatment of Cutaneous Larva Migrans: Through the Dermoscope.

Dermoscopy Before and After Treatment of Cutaneous Larva Migrans: Through the Dermoscope.

Pulse dye laser (PDL) treatment of cutaneous larva migrans in a pregnant patient

Pulse dye laser (PDL) treatment of cutaneous larva migrans in a pregnant patient

Treatment of cutaneous larva migrans with a single session of carbon dioxide laser: a study of ten cases in the Philippines.

Cutaneous larva migrans (CLM) has a detrimental effect on patients' emotional and physical quality of life. Due to local unavailability of gold standard oral treatments for CLM, carbon dioxide laser was attempted. We present a case series where a single session of carbon dioxide laser treatment was associated with cessation of signs and symptoms of CLM. The aim of this study was to assess the efficacy of a single session of carbon dioxide laser in the treatment of CLM. Ten cases (eight patients) with CLM were treated with one session of carbon dioxide laser treatment and followed up daily for the first week with photographic documentation and then weekly for the next 3 weeks to complete a 4 week follow-up period. The first cases in our series, who received one to two passes of fractional CO2 laser, experienced further larval migration for 2-3 days, after which no more progression was noted. For the next seven cases, we increased the number of CO2 laser passes to 3-4, and noted no further larval migration. At the end of the 4-week follow-up period, all CO2 laser-treated areas were completely healed, leaving postinflammatory hyperpigmentation of the serpiginous track. The results of this case series indicate the efficacy of a single session of CO2 laser in treating CLM. Further studies are required to identify the minimum number of passes required to effectively control CLM.

Tropical dermatology: cutaneous larva migrans, gnathostomiasis, cutaneous amebiasis and trombiculiasis.

In today's world, many people can travel easily and quickly around the globe. Most travel travel-related illnesses include fever, diarrhea, and skin disease, which are relatively uncommon in returning travelers. We review four of the most common emerging infestations and skin infections in the Americas, which are important to the clinical dermatologist, focusing on the clinical presentation and treatment of cutaneous larva migrans, gnathostomiasis, cutaneous amebiasis, and trombiculiasis.

Cutaneous larva migrans: Diagnosis and management

Jean Watkins discusses the life cycle, symptoms and treatment of cutaneous larva migrans, and provides practical advice on prevention.

Treatment of cutaneous larva migrans.

Cutaneous larva migrans caused by the larvae of animal hookworms is the most frequent skin disease among travelers returning from tropical countries. Complications (impetigo and allergic reactions), together with the intense pruritus and the significant duration of the disease, make treatment mandatory. Freezing the leading edge of the skin track rarely works. Topical treatment of the affected area with 10%-15% thiabendazole solution or ointment has limited value for multiple lesions and hookworm folliculitis, and requires applications 3 times a day for at least 15 days. Oral thiabendazole is poorly effective when given as a single dose (cure rate, 68%-84%) and is less well tolerated than either albendazole or ivermectin. Treatment with a single 400-mg oral dose of albendazole gives cure rates of 46%-100%; a single 12-mg oral dose of ivermectin gives cure rates of 81%-100%.

Treatment of cutaneous larva migrans: A comparison between albendazole and traditional therapy

Treatment of cutaneous larva migrans: A comparison between albendazole and traditional therapy

A Randomized Trial of Ivermectin Versus Albendazole for the Treatment of Cutaneous Larva Migrans

In an open study, we compared the efficacy of single doses of oral ivermectin (12 mg) and oral albendazole (400 mg) for the treatment of cutaneous larva migrans. Twenty-one patients were randomly assigned to receive ivermectin (n = 10) or albendazole (n = 11). All patients who received ivermectin responded and none relapsed (cure rate = 100%). All but one patient in the group receiving albendazole responded, but five relapsed after a mean of 11 days (cure rate = 46%; P = 0.017). No major adverse effects were observed. We conclude that a single 12-mg dose of ivermectin is more effective than a single 400-mg dose of albendazole for the treatment of cutaneous larva migrans.

Creeping eruption. A review of clinical presentation and management of 60 cases presenting to a tropical disease unit

Cutaneous larva migrans is an infection with a larval nematode, most frequently by dog or cat hookworms. It has a characteristic presentation that is easily recognizable. We reviewed the charts of 60 patients with cutaneous larva migrans who presented to the Tropical Disease Unit, Toronto (Ontario) Hospital, during a 6-year period. Ninety-five percent of the patients were Canadians who had recently returned from the tropics or subtropics, notably the Caribbean. Almost all patients had a linear or serpiginous, very pruritic larval track. Topical thiabendazole was efficacious in 52 (98%) of 53 patients treated. Albendazole cured six (88%) of seven patients treated. Because of adverse effects, oral thiabendazole and liquid nitrogen were not utilized. We conclude that topical thiabendazole and oral albendazole are very effective and safe modalities for the treatment of cutaneous larva migrans.

Single Dose of Albendazole in the Treatment of Cutaneous Larva Migrans

<h3>To the Editor.—</h3> The syndrome of cutaneous larva migrans, also known as creeping eruption, is a process commonly found in inhabitants of tropical or subtropical regions of the world. It is caused by penetration of the skin by infective larvae of hookworms from various animals.<i>Ancylostoma braziliense</i>, a hookworm of cats and dogs, causes most cases, although other nematodes, including<i>Ancylostoma caninum, Uncinaria stenocephala</i>, and<i>Bunostomum phlebotomus</i>are occasional causes.¹ Thiabendazole, 25 mg/kg per day orally, for two consecutive days, is currently considered the drug of choice. Alternatively, topical application of an aqueous 10% suspension of the compound (500 mg per 5 ml), has been advocated as equally effective, and essentially devoid of toxic side effects.² As thiabendazole has become unavailable in many countries, and since other suggested alternatives, such as oral or topical mebendazole, have not lived up to early expectations, any addition to the therapeutic armamentarium

Single dose of albendazole in the treatment of cutaneous larva migrans

<h3>To the Editor.—</h3> The syndrome of cutaneous larva migrans, also known as creeping eruption, is a process commonly found in inhabitants of tropical or subtropical regions of the world. It is caused by penetration of the skin by infective larvae of hookworms from various animals.<i>Ancylostoma braziliense</i>, a hookworm of cats and dogs, causes most cases, although other nematodes, including<i>Ancylostoma caninum, Uncinaria stenocephala</i>, and<i>Bunostomum phlebotomus</i>are occasional causes.¹ Thiabendazole, 25 mg/kg per day orally, for two consecutive days, is currently considered the drug of choice. Alternatively, topical application of an aqueous 10% suspension of the compound (500 mg per 5 ml), has been advocated as equally effective, and essentially devoid of toxic side effects.² As thiabendazole has become unavailable in many countries, and since other suggested alternatives, such as oral or topical mebendazole, have not lived up to early expectations, any addition to the therapeutic armamentarium

Oral albendazole for the treatment of cutaneous larva migrans

Cutaneous larva migrans is becoming more common in the U.K. with the popularity of tropical countries as holiday destinations. We describe the increasing use of a new benzimidazole derivative, albendazole, which is very effective in the treatment of cutaneous larva migrans. In contrast to thiabendazole, it is virtually free from side-effects and should, we feel, become the treatment of choice for this condition.

Treatment of cutaneous larva migrans with albendazole. Preliminary report.

Twenty three patients with Cutaneous Larva Migrans syndrome were prospectively treated with 400 mg/day of Albendazole for 3 consecutive days. Clinical response, compliance and tolerance was excellent. Patients were asymptomatic within the first 72 hours of treatment and recurrences did not occurred. Preliminary results with three additional patients suggest that a single oral 400 mg dose may be effective as well.